The funds from the Goodes prize will be used to help accelerate Dr. Watterson’s lead anti-inflammatory drug candidate, called MW150, to the point of initiating a Phase 1 clinical trial in 2017.  Dr. Watterson is collaborating with a leading scientist at Columbia University and is working on spinning out a new biotechnology company which will be responsible for commercializing this new exciting drug candidate.